Targeting of CD30-negative tumor cells in DLBCL with Brentuximab-vedotin through CD30-positive extracellular vesicles, in vitro

ABSTRACT: Evaluate the composition of extracellular vesicles by mass spectrometry coupled with liquid chromatography.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Cell Suspension Culture

DISEASE(S): Hodgkin's Lymphoma

SUBMITTER: Adriana Franco Paes Leme  

LAB HEAD: Adriana Franco Paes Leme

PROVIDER: PXD025442 | Pride | 2022-02-17

REPOSITORIES: Pride